Phenomenome, Polymedco Ink Pact to Commercialize Mass Spec-based Colorectal Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Phenomenome Discoveries has granted Polymedco Cancer Diagnostic Products a license to commercialize Phenomenome's mass spectrometry-based blood test for colorectal cancer in the US.

The test uses triple quadrupole mass spec technology to detect a deficiency in novel anti-cancer and anti-inflammatory metabolites in a blood sample, which Phenomenome said it has discovered occurs in nine out of 10 patients with colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.